Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of Insulin Detemir in Combination With OAD in Type 2 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Type 2 diabetes for at least 12 months since diagnosis~* Insulin naive subjects~* OAD treatment for at least 4 months alone or combined with no more than two OADs~* Body mass index (BMI) below 35.0 kg/m2~* HbA1c between 7.5-10.0%~* Able and willing to use twice a day injections for the entire trial period~Exclusion Criteria:~* Current or previous treatment with thiazolidiones within the last 6 months~* OAD treatment with three or more OADs within the last 6 months~* Acute insulin treatment for longer than 7 days in a row within the last 6 months~* Secondary diabetes~* Known maturity onset of diabetes of young (MODY)~* Known or suspected allergy to trial product or related products

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).